中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1063 records (took 0.034 seconds)

    System for placement optimization of chip design for transient noise control and related methods thereof
    61.
    发明授权
    System for placement optimization of chip design for transient noise control and related methods thereof 有权

    公开(公告)号：US11436401B2

    公开(公告)日：2022-09-06

    申请号：US16571773

    申请日：2019-09-16

    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

    Inventor： Ke Wang ,  Kevin Skadron ,  Mircea R. Stan ,  Runjie Zhang

    IPC: G06F30/39 ,  G06F30/367 ,  G06F30/392 ,  G06F119/10

    Abstract: Transient voltage noise, including resistive and reactive noise, causes timing errors at runtime. A heuristic framework, Walking Pads, is introduced to minimize transient voltage violations by optimizing power supply pad placement. It is shown that the steady-state optimal design point differs from the transient optimum, and further noise reduction can be achieved with transient optimization. The methodology significantly reduces voltage violations by balancing the average transient voltage noise of the four branches at each pad site. When pad placement is optimized using a representative stressmark, voltage violations are reduced 46-80% across 11 Parsec benchmarks with respect to the results from IR-drop-optimized pad placement. It is shown that the allocation of on-chip decoupling capacitance significantly influences the optimal locations of pads.

    Compositions and methods for regulating blood pressure
    66.
    发明授权
    Compositions and methods for regulating blood pressure 有权

    公开(公告)号：US11376305B2

    公开(公告)日：2022-07-05

    申请号：US16382269

    申请日：2019-04-12

    Applicant: University of Virginia Patent Foundation

    Inventor： Brant E. Isakson ,  Marie Billaud ,  Leon J. DeLalio ,  Thu Le

    IPC: A61K38/08 ,  A61K38/16 ,  A61P9/08 ,  A61P9/00 ,  A61K38/10 ,  C07K14/705 ,  C07K7/06 ,  C07K14/16 ,  A61K38/20 ,  A61K38/00

    Abstract: Both purinergic signaling through nucleotides such as ATP and noradrenergic signaling through molecules such as norepinephrine regulate vascular tone and blood pressure. Pannexin1 (Panx1), which forms large-pore, ATP-releasing channels, is present in vascular smooth muscle cells in peripheral blood vessels and participates in noradrenergic responses. Using pharmacological approaches and mice conditionally lacking Panx1 in smooth muscle cells, we found that Panx1 contributed to vasoconstriction mediated by the α1 adrenoreceptor (α1AR), whereas vasoconstriction in response to serotonin or endothelin-1 was independent of Panx1. Analysis of the Panx1-deficient mice showed that Panx1 contributed to blood pressure regulation especially during the night cycle when sympathetic nervous activity is highest. Using mimetic peptides and site-directed mutagenesis, we identified a specific amino acid sequence in the Panx1 intracellular loop that is essential for activation by α1AR signaling. Collectively, these data describe a specific link between noradrenergic and purinergic signaling in blood pressure homeostasis.

    SYSTEM AND METHOD FOR ARTIFICIAL PANCREAS WITH MULTI-STAGE MODEL PREDICTIVE CONTROL
    67.
    发明申请
    SYSTEM AND METHOD FOR ARTIFICIAL PANCREAS WITH MULTI-STAGE MODEL PREDICTIVE CONTROL 有权

    公开(公告)号：US20220203029A1

    公开(公告)日：2022-06-30

    申请号：US17611323

    申请日：2020-05-14

    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

    Inventor： Marc D. Breton ,  Jose Garcia-Tirado ,  Patricio Colmegna ,  John Corbett

    IPC: A61M5/172 ,  G16H50/20 ,  A61B5/00 ,  A61B5/145 ,  G16H20/17

    Abstract: Provided are a system and method for an artificial pancreas having multi-stage model predictive control to minimize and/or prevent occurrence of hypoglycemia associated with Type 1 diabetes. The control implements predictive modeling of a probability of glucose uptake associated with exercise based on at least one exercise profile for a subject with Type 1 diabetes. Based on the probability, the control implements an automatic adjustment of basal insulin infusion to counteract a risk of exercise-induced hypoglycemia in advance of the subject engaging in the exercise. The control implements adjustment of such infusion based on real-time signaling of exercise likely to induce hypoglycemia. The control implements adjustment of a meal-time bolus to account for delay in glucose uptake resulting from exercise engaged in by the subject. Consequently, the control acts to minimize and/or prevent hypoglycemia from occurring both during and immediately after exercise.

Patent Agency Ranking